

Annex I

List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, applicants / marketing authorisation holders in the Member States

Member State EU/EEA	Marketing authorisation holder company name, address	Applicant company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration
Denmark	Hexal A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark		Methylphenidate "Hexal"	18 mg	Prolonged-release tablet	Oral use
Denmark	Hexal A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark		Methylphenidate "Hexal"	36 mg	Prolonged-release tablet	Oral use
Denmark	Hexal A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark		Methylphenidate "Hexal"	54 mg	Prolonged-release tablet	Oral use
Germany		Hexal A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark	Methylphenidath ydrochlorid HEXAL 18 mg Retardtabletten	18 mg	Prolonged-release tablet	Oral use
Germany		Hexal A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark	Methylphenidath ydrochlorid HEXAL 36 mg Retardtabletten	36 mg	Prolonged-release tablet	Oral use
Germany		Hexal A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark	Methylphenidath ydrochlorid HEXAL 54 mg Retardtabletten	54 mg	Prolonged-release tablet	Oral use
Ireland	Rowex Ltd Bantry Co. Cork Ireland		Metidate XL 54mg Prolonged- Release Tablets	54 mg	Prolonged-release tablet	Oral use
Ireland	Rowex Ltd Bantry Co. Cork Ireland		Metidate XL 18 mg Prolonged- Release Tablets	18 mg	Prolonged-release tablet	Oral use

Member State EU/EEA	Marketing authorisation holder company name, address	Applicant company name, address	(Invented) Name	Strength	Pharmaceutical form	Route of administration
Ireland	Rowex Ltd Bantry Co. Cork Ireland		Metidate XL 36 mg Prolonged- Release Tablets	36 mg	Prolonged-release tablet	Oral use